Vancouver, British Columbia, Canada, July 25, 2025 – PanGenomic Health Inc. (“PanGenomic Health” or the “Company”) (CSE: NARA) is pleased to provide a corporate update on recent strategic initiatives.
NaraCare.AI Platform Strategy
“PanGenomic Health is pleased to announce that it is developing a new AI health platform for personalized alternative health products”, said Maryam Marissen, President & CEO of PanGenomic Health. “Consumers and their health practitioners face challenges in understanding which alternative health products are right for the whole health of an individual, and we believe that our NaraCare.AI platform can become the trusted source for consumers and practitioners across North America.”
A holistic approach to health and wellness requires listening to what the mind and body are saying. The NaraCare.AI platform will leverage insights and functionality developed in our Nara mental health app, our Mindleap telehealth platform and our Mujn diagnostic tools. Built using leading AI models, the NaraCare.AI platform will present relevant information to consumers or their health practitioner about personalized alternative health treatments, including evidence-based information about benefits, dosage use, adverse effects and drug interactions. Users will also have access to an online eCommerce site to purchase alternative health products.
The Nara mental health app design recognizes that each person’s journey is unique with personalized insights into alternative health options based on customers’ medication, mood and biological factors. The app was designed for personalization by reviewing pharmacogenomics, nutrigenomics and proteomics research data about natural remedies alongside an individual’s genomic and ongoing proteomic data. The Mindleap telehealth platform is designed to provide online access to a broad range of alternative health practitioners. The Mujn diagnostic tools have
been developed to track changes in specific biomarkers relevant to natural remedy treatment regimens.
The Company expects to launch the Nara eCommerce shopping site in the third quarter of 2025
and the NaraCare.AI platform by the fourth quarter of 2025.
Acceleration of Warrant Expiration Date
The Company also provides an update regarding the 7,500,000 share purchase warrants issued by the Company on or about January 10, 2025, which warrants are exercisable for $0.13 per share (the “Warrants”). As the closing price of the Company’s shares, as quoted by the Canadian Securities Exchange, was equal to or greater than $0.26 per share for a 10 consecutive trading day period ending on July 24, 2025, the Company announces that the expiration date of the Warrants will be accelerated to August 25, 2025 at 5 pm PST. The Company expects to use any warrant exercise proceeds for general corporate and working capital purposes.
About PanGenomic Health
PanGenomic Health is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. The Company’s initial focus is to support mental health. Registered as a British Columbia benefit company, PanGenomic Health’s mission is to promote and improve the health and wellness of people and society by providing a technology platform that identifies plant-based solutions tailored to the health profile of each individual.
For more information, please contact:
Jerry Lai, Investor Relations
PanGenomic Health Inc.
+1 778 743 4642
ir@pangenomic.com
Fairfax Partners Inc.
Daniel Southan-Dwyer, President
+1 604 366 6277
connect@fairfaxpartners.ca
This news release includes certain statements that may be deemed “forward-looking statements”,
including statements respecting the services to be provided by PanGenomic Health and the
consideration to be paid to PanGenomic Health. The use of any of the words “anticipate”,
“continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar
expressions are intended to identify forward looking statements. Although PanGenomic Health
believes that the expectations and assumptions on which the forward-looking statements are
based are reasonable, undue reliance should not be placed on the forward-looking statements
because PanGenomic Health can give no assurance that they will prove to be correct. Since
forward-looking statements address future events and conditions, by their very nature they involve
inherent risks and uncertainties. These statements speak only as of the date of this News
Release. Actual results could differ materially from those currently anticipated due to a number of
factors and risks including various risk factors discussed in PanGenomic Health’s disclosure
documents which can be found under PanGenomic Health’s profile on www.sedarplus.ca.
The Canadian Securities Exchange has neither approved nor disapproved the information
contained herein and does not accept responsibility for the adequacy or accuracy of this
news release.
